Home>Topics>Funds>iShares Nasdaq Biotechnology

iShares Nasdaq Biotechnology

  1. All
  2. Commentary
  3. Headlines
  1. Should I buuy IBB ?

    Commentary

    Sat, 23 May 2015

    I am looking to increase my healthcare/biotech allocation to 15% (from 10%) and thinking of starting investing in IBB . Do you think it is a wise move? The price has skyrocketed in the last 2-3 years, so I do not know whether it is the right

  2. Fitch Affirms IDRs of 6 German Financial Institutions and ZKB; Withdraws SRFs

    Headlines

    Thu, 21 May 2015

    and Support Rating Floors (SRF) at 'AAA' and withdrawn the SRFs. The four banks are NRW.BANK; Investitionsbank Berlin ( IBB ), Investitionsbank Schleswig-Holstein (IB.SH) and Landeskreditbank Baden-Wuerttemberg - Foerderbank (L-Bank

  3. Healthcare Investments

    Commentary

    Wed, 8 Apr 2015

    I have around 35K that I am planing on investing primarily in Heathcare ETFs spread between IBB , BBH, PBE and PBP. Is healthcare a good option now. Almost all the funds are up 20% YTD and I am wondering if the bull run is almost ending.

  4. From Barron’s, February 2, 2015 (Part 1)

    Commentary

    Sat, 31 Jan 2015

    Bank of China [3988.hk], WynnMacau [1128.hk], SJMHoldings [880.hk], Singapore REITs . Short – SOXX, SOCL, IBB , Australian dollar Herro: Cie.FinanciereRichmont [CFR.sw], DEO, TM, BNPParibas [BNP.fr] Shafer: CCOI, NICE

  5. What to own, not own, when rates go up?

    Commentary

    Fri, 26 Dec 2014

    I really like VNQ, should I sell before rates go up? Will XLU be killed? What about IBB ? Probably don't want bonds, or treasuries, like: EDV, TLT, or BOND? Any thoughts?

  6. Why the Short-Term Tumult?

    Headlines

    Mon, 28 Apr 2014

    rose 32.4%. Possibly the most dramatic example of momentum loss is in the biotechnology sector. The iShares NASDAQ Biotechnology ( IBB ), an exchange-traded fund, appreciated 65% in 2013. From the start of 2014 through February, the

  7. HQH/HQL

    Commentary

    Fri, 18 Apr 2014

    the biotechs, including HQH/HQL. The Nasdaq Biotech Index (^NBI) is down 19% from the late February highs, along with IBB , a benchmark ETF, and the CEFs, when the latter are adjusted for distributions. They all seem to have stabilized this week

  8. From Barron’s, March 24, 2014 (Part 2)

    Commentary

    Sat, 22 Mar 2014

    that for longer-term, go passive for stock funds and active for bond funds. Pg 35: Biotechs are hot and the related ETFs [ IBB , XBI ] are attracting huge inflows [YTD inflows are already more than those for entire 2013]. The P/E of XBI is 33 excluding

  9. Biotech IPOs: What to Learn from a Banner Year

    Headlines

    Thu, 23 Jan 2014

    including Epizyme, Agios Pharmaceuticals and Chimerix. Because the index serves as the basis for the iShares Nasdaq Biotechnology Index Fund, which is an exchange traded fund (ETF), any company added to it automatically gains access

  10. Zacks.com

    Commentary

    Sat, 7 Dec 2013

    Pacific (Emerging) ETFs, Financials, and two Small Cap ETFs came up also but the big category turned out to be HealthCare. IBB at 12.23%, BBH up 11.71% and XBI up 12.21% to name a few. I counted 12 ETFs up over 6% in the 1 Mon (%). I'm

« Prev12Next »
Content Partners